CPA6: A Potential Drug Target and Biomarker for Carboxypeptidase B

Target Name: CPA6

NCBI ID: G57094

CPA6

CPA6: A Potential Drug Target and Biomarker for Carboxypeptidase B

Carboxypeptidase B (CPA6) is a enzyme that plays a crucial role in the detoxification of peptides and proteins in the body. It is a cytoplasmic protein that is expressed in various cell types, including epithelial, hepatic, and neural cells. CPA6 has been identified as a potential drug target and biomarker due to its unique structure and its involvement in several cellular processes. In this article, we will discuss the biology of CPA6, its potential as a drug target, and its role as a biomarker for various diseases.

Structure and Function

CPA6 is a 25 kDa protein that consists of 156 amino acid residues. It has a characteristic Rossmann-fold that is responsible for its unique structure and function. The Rossmann-fold is a type of hydrogen bonding that forms a specific arrangement of secondary structure elements, including alpha helices and beta-sheets. This unique structure allows CPA6 to interact with small molecules and other proteins in a precise and specific manner.

CPA6 is involved in the detoxification of peptides and proteins, which is critical for maintaining cellular homeostasis and regulating various cellular processes. It is a critical enzyme for the detoxification of peptides, such as amino acids, peptides, and neurotransmitters. CPA6 also plays a key role in the degradation of damaged proteins, which is essential for maintaining cellular quality control and preventing the formation of harmful cellular aggregates.

CPA6 has also been shown to play a role in cell signaling, particularly in the regulation of cell adhesion and migration. It has been shown to interact with several cytokines and signaling molecules, including TGF-β, Wnt, andNotch. These interactions may have implications for the regulation of cellular processes, including cell growth, differentiation, and angiogenesis.

Potential Drug Target

CPA6 has been identified as a potential drug target due to its unique structure and its involvement in several cellular processes. One of the main reasons for its potential as a drug target is its involvement in the detoxification of peptides and proteins, which can be targeted by small molecules, such as drugs that interfere with its function.

Another reason for its potential as a drug target is its role in cell signaling, particularly in the regulation of cell adhesion and migration. This may make it a useful target for drugs that are aimed at modulating these processes, such as those that target tyrosine kinases or intracellular signaling pathways.

Biomarker

CPA6 has also been identified as a potential biomarker for several diseases. Its unique structure and its involvement in several cellular processes make it an attractive target for diagnostic tools. For example, CPA6 has been shown to be expressed in various tissues and cells, including brain, liver, and cancer cells. This suggests that it may be a useful biomarker for diseases that affect these tissues, such as neurodegenerative diseases, cancer, or diseases that affect the liver.

Another potential application of CPA6 as a biomarker is its involvement in cell signaling. Its role in the regulation of cell adhesion and migration makes it a potential target for drugs that are aimed at modulating these processes. This may make it a useful biomarker for diseases that affect these processes, such as cancer or neurodegenerative diseases.

Conclusion

In conclusion, CPA6 is a unique enzyme that plays a critical role in the detoxification of peptides and proteins, as well as in cell signaling. Its structure and function make it an attractive target for small molecules and drugs that aim to modulate its function. As a potential drug target and biomarker, CPA6 may have

Protein Name: Carboxypeptidase A6

Functions: May be involved in the proteolytic inactivation of enkephalins and neurotensin in some brain areas. May convert inactive angiotensin I into the biologically active angiotensin II (PubMed:18178555). Releases a C-terminal amino acid, with preference for large hydrophobic C-terminal amino acids and shows only very weak activity toward small amino acids and histidine (PubMed:20855895)

The "CPA6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPA6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets